Member Info for daveycaferacer

Huge volume on NASDAQ recently, and today we already have 75,00 in the first 30 mins, equivalent to half a days trading on average

Mike is getting bad advice, there is no point pursuing legal action against a Company that has no money, he'll just be wasting more money in a vendetta that Sports Direct Shareholders won't thank him for.

I did have a holding, which if I had retained it would be worth >£1m

Whilst my current holding is not worth quite that amount it certainly will be going forward ;o-)

New note released today:-

https://www.trinitydelta.org/research-notes/aacr-2019-savolitinib-in-the-spotlight-in-nsclc/

Unfortunately not

Unfortunately litigation against a Company that has gone into Administration and its Directors never works. They are broke, there is no money to recoup.

Another institution meets its end due to Brexit? I think you will find Debenhams has >£500m of debt, I doubt remaining in the rancid EU would help it somehow ffs

I agree and in this context I like to amend Buffett's well known phrase

"If you aren’t willing to own a stock for ten years, don’t even think about owning it for ten minutes”

to

"If you aren’t willing to own a stock for ten years, don’t even think about owning it for a year”

I've owned for 10 years and will be owning for a further 10

Thanks for posting Djingle

Since the pipeline issues and the subsequent huge drop in late Dec I've noticed most of the models these chart websites use are very flawed, as they use historical data with no regard for material events. In this case I see the model predicts the ADR's will be $25 by early 2020, presumably based on chart technicals that are completely out step with reality (eg. based on the 40% drop in Dec).

I also get alerts form various American based sites (Zacks for example) who issue a recommendation and then the reverse the following day, eg. Zacks issued a Sell on the stock Friday and a Buy today, and will probably issue a Sell tomorrow or Wednesday!

I personally prefer to use my own judgement and 2 Warren Quotes which I think are very applicable to Chi-Med:-

"If you aren’t willing to own a stock for ten years, don’t even think about owning it for ten minutes”

“Price is what you pay; Value is what you get.”

I've held off and on for the past 10 years and now only Buy and will continue to do so for the next 10 years,

https://www.thepharmaletter.com/article/contenders-line-up-to-steal-the-show-at-aacr-2019?mc_cid=2de0e551ee&mc_eid=39aa759c0d

CEO Interview on CNBC's Squawk Box a few days ago

https://finance.yahoo.com/quote/HCM?p=HCM&.tsrc=fin-srch

amones, certainly Vhi-Med will benefit in terms of the agreement/contract with Astra, the key terms of which are:-

Development costs: AZ pay 100% ex-China (excl. $50m by Chi-Med) & 75% development cost in China (Chi-Med 25%);

14-18% tiered royalty ex-China & 30% flat rate China royalty on all product revenues.

The revenue opportunity across all indications and in all territories is quantifies in billions of $

Unfortunately amones AZ already own the global rights but I’m hoping the market wil, start to place greater value on Chi Med’s share

AACR Video on TATTON trial

https://oncology.medicinematters.com/non-small-cell-lung-cancer/savolitinib/tatton-trial-options-for-egfr-inhibitor-resistant-nsclc/16588432

lots of social media postings, tweets and updates from AACR such as this:-

https://twitter.com/LeciaSequist/status/1112436012884656129

It seems there's more traffic on Savolitinib than any other drug candidates, quite a lot of excitement from what I can see

From today's AACR in Atlanta - Chi_Med has filing in its sights

http://www.evaluate.com/vantage/articles/events/conferences/aacr-2019-chi-med-has-savolitinib-filing-its-sights

AACR Fierce Pharma update today on Savo/Tagrisso combination

https://www.fiercepharma.com/pharma/chi-med-astrazeneca-s-savolitinib-helps-some-tagrisso-resistant-egfr-lung-cancer-patients

Good evening Jatw

Interesting deal with Daiichi regarding their HER2 Breast Cancer drug that is expected to be a blockbuster with $4.5bn p.a. global peak sales. I think it is interesting in terms of how much AZ are willing to pay to get rights to the asset. I am not sure it has any direct impact on Savolitinib but it will be interesting to draw parallels in terms of how the market values assets like Savolitinib.

My experience of valuation between something in 1st and 2nd/3rd line is limited, but certainly the potential patient population in 1st line is usually much larger of course.

I am going to read some further coverage on the AZ Daiichi deal further.

McKinsey & Co. commentary on China Biotech part 2 - published yesterday

https://www.linkedin.com/pulse/chinese-biopharmass-cambrian-explosion-5-tips-success-franck-le-deu/

https://www.bloomberg.com/news/articles/2019-03-23/china-pledges-stronger-reform-on-approving-monitoring-new-drugs?utm_medium=social&utm_campaign=socialflow-organic&utm_source=twitter&utm_content=nextchina